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INTRODUCTION 
Vitronectin is a multifunctional adhesive glycoprotein present in mammalian 
plasma and the extracellular matrix of many tissues (1). This adhesive protein circulates 
in human plasma at concentrations of 200-400~g/ml, and serves as a regulatory protein in 
humoral defense mechanisms through interactions of macromolecules in cascades of 
coagulation and fibrinolysis (2). Some target macromolecules that interact with 
vitronectin include: heparin, PAl -1 (plasminogen activator inhibitor-I), proteases such as 
thrombin, serine protease inhibitor-protease complexes, and a sub-class of integrin 
receptors on the surface of cells (3). The anti-fibrinolytic protein, PAl-I, is a major 
inhibitor of tissue-type plasminogen activator (tP A), and urokinase-type plasminogen 
activator (uPA) (4-6). Like other serpins, PAI-1 has a reactive loop mimicking the 
substrate of its target proteases (7). The active conformation of PAl -1 is relatively 
unstable. Therefore, the protein undergoes a rapid conversion to a latent form, 
characterized by the insertion of the reactive loop into a centrall3-sheet within the 
molecule (8). Binding to vitronectin stabilizes the active conformation of PAI-1 , 
resulting in a 2 to 3 fold increase in its half-life (9,10). This stabilization of PAI-1 is 
thought to arise from the restriction of l3-sheet movement and thus the prevention of the 
insertion ofthe reactive loop as a result of binding to vitronectin (11). Recent work has 
localized the PAI-1 binding site to the N-terminal Somatomedin B region of vitro nee tin, 
consisting of the first 44 amino acid residues of the protein (12). Deng et al. (13) 
generated chimeras between fragments of the vitronectin Somatomedin B domain and 
other complementary sequences in inactive Somatomedin B homology domains. This 
study indicates that the essential elements for PAl -1 binding are located between residues 
12 and 30 ofvitronectin. In addition, alanine mutagenesis revealed that eight cysteines, 
Gly-12, Asp-22, Leu-24, Tyr-27, Tyr-28, and Asp-34 are vital to PAI-l binding activity 
(13). 
In order to gain further insight into the PAl -1 binding site of vitronectin, site-
directed mutagenesis will be used to identify residues involved in particular 
macromolecular interactions. While most of the recombinant work has relied on 
fragments expressed in E. coli, an insect cell line has been developed in Dr. Cynthia 
Peterson's lab to express full-length recombinant vitronectin. Using the Bac-to-Bac 
Baculovirus Expression System, two full-length mutant forms of vitronectin, as well as 
the "wild-type" version have been expressed. Alanine mutagenesis of Tyr-27, and Tyr-
28, are the two mutants manipulated during this study. Upon expression of the mutant 
proteins, competitive Elisa assay will be used to evaluate the specific PAI-l binding 
properties of "wild-type" vitronectin, the Y27 A, and the Y28A mutant forms of 
vitronectin. Unfortunately, the project did not progress as far as desired. Therefore, the 
Elisa assay analysis of the mutant vitronectin will not be discussed here. 
MATERIALS AND METHODS 
Two mutants of the protein vitronectin were generated using PCR by Dr. Cynthia 
Peterson. Both mutations are amino acid substitutions, one at position 27, substituting an 
alanine for a tyrosine, and the other at position 28, again substituting an alanine for a 
tyrosine. The procedure for expressing these mutants is described below. 
Transforming bacteria. The day before the transformation, an overnight culture of 
MVl190 cells was prepared. An autoclaved wooden stick was dipped into the MV1190 
cells and then dipped into 2mL of Luria Broth (LB) in a flame sterilized, autoclaved 
13xlOO-glass tube. The cells grew overnight, shaking at 37°C. The following day, 
20mLs of LB was inoculated in an autoclaved klett flask with 200llL of the overnight 
culture. This was grown with shaking at 37°C for approximately 3 hours or until a klett 
reading between 40 and 60 was obtained. 10mLs of cells was placed into each of two 
14mL Falcon Tubes. The cells were then spun down in a Beckman centrifuge at 
4000rpm, 4°C for lO minutes. After the cells were spun down, they were resuspended in 
lmL TSB (solution preparation: 10mL LB, Ig PEG-8000, .SmL DMSO, .1mL MgCI2, .1 
mL MgS04, sterile filtered and stored in refrigerator). The cells were then placed on ice 
for 10 minutes. The cells are now competent to take up plasmid DNA. For both the 
Y27A and Y28A mutants, lJ.lL of DNA was added to 100J.lL of these competent cells, 
and mixed by pipetting up and down. The cells were then placed on ice for another 30 
minutes. Afterwards, .4mL ofTSBG (solution preparation: SmL TSB, 72J.lL 25% 
glucose, sterile filtered and stored in refrigerator) was added to the cells and shaken at 
37°C for 1 hour. For both the Y27A and Y28A mutants, lS0J.lL of the transformed cells 
was spread on LB agar plates with ampicillin. The plates were allowed to sit upright for 
5-10 minutes, and then inverted and placed in a 37°C room overnight. The next day 
overnight mini-preps of the colonies ofY27A and Y28A DNA was prepared. 6 mini-
preps for each mutant, consisting of2mL LB and an isolated bacteria colony (selected 
using a sterile stick), were placed in the 37°C room overnight. The following day the 
DNA for each mutant was isolated using the following procedure. 
DNA isolation. 1.SmL of the cells from each of the overnight mini-preps was transferred 
to Eppendorftubes. Then the cells were spun down for S minutes at 10,000 rpm. The 
supernatant was removed and the cells were spun down again for 1 minute to remove any 
residual supernatant. The DNA was then isolated using the QIA prep Spin Miniprep 
Kit(2S0). The protocol from pages 16 and 17 was followed from the procedural manual 
included with the kit in order to properly isolate the DNA for the Y27 A and Y28A 
mutants. A restriction digest of the DNA was performed to verify that the DNA plasmid 
contained the gene of interest. 
Restriction Digest. A 1 % agarose gel was prepared using 1 g of agarose and 100mL TBE 
(.Sx). To digest the DNA, lSJ.lL of water, 3J.lL of DNA, 2J.lL of appropriate buffer, IJ.lL 
of BamHI, and 1 J.lL of HindIII, was added to an Eppendorf tube and placed in a 37°C 
room for 1 hour. The entire 20J.lL was loaded onto the gel, and run for approximately 1 
hour. The presence of the gene of interest was verified using Ethidium Bromide staining. 
A picture of the gel was taken for record keeping purposes. 
Transformation of DHI OBac cells with Y27 A and Y28A plasmid DNA. The purpose of 
this procedure was to create the recombinant bacmid DNA for each mutant that was used 
to infect the insect cell lines. LB plates were prepared containing: SOJ.lg/mL kanamycin, 
7J.lg/mL gentamicin, lOJ.lg/mL tetracycline, 300J.lg/mL Bluo-gal, and 40J.lg/mL IPTG. 
The procedure from page 8 of the instruction manual for the Bac-to-Bac Baculovirus 
Expression System from Life Technologies was followed in order to transform the 
DHI0Bac cells with the Y27 A and Y28A DNA. The cells were then plated out onto the 
previously mentioned LB plates. A blue/white screen was used to determine colonies 
containing the Y27A and Y28A bacmid DNA. The procedure manual says to incubate 
the plates for 24 hours, but an incubation time of 28 hours seemed to be optimal to 
distinguish truly white colonies from truly blue colonies. 
Isolation of the recombinant bacmid DNA. Again, the procedure from pages 8 and 9 of 
the instruction manual for the Bac-to-Bac Baculovirus Expression System from Life 
Technologies was followed in order to isolate the Y27 A and Y28A bacmid DNA. A 
restriction digest was then performed to verify the presence of the desired gene following 
the restriction digest procedure described above. 
Transfection of the S19 insect cell line with the recombinant bacmid DNA. 360xlSmm 
/ 
petri dishes were seeded with 900llL of Sf9 cells at 9* 10AScells/mL, and IIOOIlL of ex-
cell 420 without antibiotics. The cells were allowed to adhere for one hour. In the mean 
time, two solutions were prepared. Solution A contained SilL of mini-prep bacmid DNA 
and IOOIlL ex-cell 420 for each transfection. Solution B contained 61lL ofCellFECTIN 
reagent and IOOIlL of ex-cell 420 for each transfection. The solutions were combined 
and allowed to sit for 4S minutes. After the cells had adhered to the plates, they were 
washed with 2mL of ex-ce11420 medium .. 8mL of ex-cell 420 was then added to each 
tube containing the mix of solution A and B. This entire mL was then overlaid onto the 
cells. The cells were then allowed to incubate for S hours at 27°C. After S hours, the 
transfection material was removed and 2ml of ex-cell 420 was added to each dish. The 
cells were then allowed to incubate at 27°C for 48 hours. 
Harvesting Virus Stock. Each time the cells needed to be harvested, the volume of cells 
is transferred to Eppendorf tubes, since the virus stock is produced on 3mL scales, 
approximately I.SmL is added to each of two Eppendorf tubes for each transfection. The 
cells are spun down at SOOO g for S minutes. The supernatant is then transferred to new 
Eppendorftubes. Both cells and supernatant are stored in the freezer, protected from 
light. 
Amplification a/Virus Stock. For each mutant, more virus stock is generated by adding 
2SIlL of previous supernatant virus stock to 3mL ofSf9 cells at 1 *10A6cells/mL. The 
cells are incubated for three days and then amplified again. After each amplification the 
cells are checked for protein production. 
Protein Production Verification. To verify protein production, a Western Blot procedure 
was used. Sf9 cells were diluted in SDS page dye, and then boiled for S minutes. 1 o ilL 
of each sample was then loaded onto the SDS page, polyacrylamide gel. A positive 
control, and a molecular weight marker was also loaded onto the gel each time a Western 
Blot was done. A primary antibody to the vitronectin protein, followed by a secondary 
antibody to the primary antibody, and then developer solution produced an enzyme 
reaction that showed a blue band indicating the protein vitronectin. The molecular 
weight marker was used to verify the molecular weight of the protein to be 77kDa. 
Infection of Hi5 insect cells. After a working quantity of virus stock was obtained 
following the repeated amplification and harvesting procedure for Sf9 cells, HiS cells 
were grown to a quantity of 11. At lL of 1 *10A6cells/ml of HiS cells, 8.33mL of virus 
stock was added to infect the HiS cells. 8.33mL was used according to the concentration 
ratio of2SIlL of stock at 3mL, and 8.33mL at lL of cells. After three days, the HiS cells 
were harvested. This first infection of HiS cells was done with the Y28A bacmid DNA. 
However, a Western Blot revealed no presence ofthe protein vitronectin. The procedure 
for the infection of HiS cells was repeated for the Y27A mutant. Again, a Western Blot 
revealed the absence of the mutant protein vitronectin. In the shortage of time, the 
infection of HiS cells was reduced down to 20mL instead of 11. 166.671lL of virus stock 
was added to the cells. This was done for both mutants. After the three day incubation 
period, the Western Blot procedure was used to verify the presence of mutant protein. 
Alas, there was no band to be seen. Unfortunately, the project did not get as far as 
desired, and so the actual testing of P AI-l binding effects using a competitive ELISA 
assay was not done. 
RESULTS 
The transformation of bacteria using the Y27A and Y28A peR generated DNA 
was successful. Overnight mini-preps of isolated colonies of bacteria were made in order 
to generate a large number of replicates of the mutant gene within the bacterial plasmid. 
This bacterial plasmid, containing either the Y27 A gene or the Y28A gene, was isolated. 
This plasmid DNA was then tested by a restriction digest using restriction enzymes, 
BamHI and HindIII. Figure 1 represents the restriction 
digest results. The lower band indicates the mutant 
vitronectin gene. The upper band indicates the rest of the 
plasmid DNA. Lanes 1 through 6 are the Y27 A plasmid, 
while lanes 7 through 13 are the Y28A plasmid. The digest 
verified the presence of the mutant gene for all of the 
samples, except for one sample ofthe Y28A gene in lane 10. Figure 1 
This plasmid DNA was then used to transform DH1 OBac cells in order to 
generate the recombinant bacmid DNA used to infect the insect cell lines. lllL of DNA 
was used to infect 100llL of competent DH1 OBac cells. The cells were serially diluted in 
the following manner, 1: 1 0, 1: 1 00, and 1: 1 000. Undiluted cells, and all the serial 
dilutions were plated on the previously prepared Luria Agar plates. However, after 24 
hours the undiluted plates showed little growth, while the serially diluted plates showed 
even less or no growth. The transformation for each mutant was redone using 31lL of 
Y27 A plasmid DNA, and SilL of Y28A plasmid DNA. In addition, the cells were spun 
down and resuspended in order to obtain a higher concentration of cells when plating. 
The results were an increased amount of growth for both mutants. 8 isolated colonies 
were streaked onto new plates to verify that the colonies were really white colonies, and 
so contained the desired bacmid DNA. 8 colonies were selected, 4 from the Y27 A plates 
and 4 from the Y28A plates. After incubation at 37°C for 24 hours, an overnight mini-
prep of a large white isolated colony for each of the two mutants was prepared. The 
mini-preps seemed to contain a good concentration of cells, and so the bacmid DNA was 
isolated for each of the mutants from these preps. Again, a restriction digest, using 
enzymes BamHI and HindIII, was used to verify the presence of the mutant gene in the 
bacmid DNA. The presence of the gene was indeed detected by the restriction digest. 
However, the bands were very faint. A representation ofthis restriction digest is not 
shown because the faint bands could not be seen clearly when the picture of the 
restriction digest was scanned in. 
The isolated bacmid DNA for each mutant was used to infect the insect cell lines. 
Initially, three infections ofSf9 cells was done, one of the Y27A DNA and two of the 
Y28A DNA. After three amplifications of these infections, a Western Blot was used to 
verify the presence of the mutant protein vitronectin. The bands were faint, although they 
seemed to become darker with the increasing amplifications, indicating the increasing 
concentration of the mutant protein. After the fourth amplification, a Western Blot 
showed a distinct band at 77kDa for the infections, the mutant vitronectin protein. Figure 
2 represents the Western Blot after the 
fourth amplifications. Lane 1 is the Y28A 
mutant protein. Lane 2 is the Y27 A mutant 
protein. Lanes 3 and 4 are deglycosylation 
mutants of vitronectin. Lanes 5 and 7 show leakage Figure 2 
from lane 6 which is the vitronectin positive control. Finally, lane 8 is the molecular 
weight marker. 
A test infection ofRiS cells on a 3mL scale, using the Y28A DNA, was done to 
determine the concentration of virus stock needed to produce the desired amount of 
protein. Since HiS cells secrete protein much better than Sf9 cells. A Western Blot of 
the HiS supernatant was done, as opposed to the 
Western Blot of the actual cells. The amounts of 
virus stock used to infect the HiS cells were 10J.tL, 
2SJ.tL, SOJ.tL, and 100J.tL. Figure 3 represents the 
Western Blot ofthe HiS test infection. Lane 1 is 
the molecular weight marker. Lane 3 is the vitronectin Figure 3 
positive control. Lane S is a deglycosylation mutant of vitro nee tin. Lane 7 is the 10J.tL 
infection of the HiS cells. Lane 8 is the 2SJ.tL infection. Lane 9 is the SOJ.tL infection. 
Lane 10 is the 100J.tL infection. From the Western, 2SJ.tL seemed to be the optimal 
volume of virus stock to infect 3mL of cells. Scaling this ratio up, 8.33mL of virus stock 
was needed to infect lL of HiS cells. After the infection of lL of HiS cells with Y28A 
DNA, a Western revealed the absence of mutant 
vitronectin protein. Figure 4 represents the Western Blot 
of the absence of the mutant vitronectin protein. Lanes 1 
and 2 were supposed to show the mutant protein. Lane 4 
is the vitronectin positive control. Lane S is the 
molecular weight marker. The procedure was repeated 
for the Y27 A mutant, and again after the infection 
Figure 4 
procedure of 1 L of Hi5 cells, a Western revealed the absence of mutant vitronectin 
protein. In the interest of time, the infection of Hi5 cells was repeated on a 20mL scale. 
However, after infection, Western Blots showed no expression ofthe mutant vitronectin 
protein. Figures for these Western Blots are not represented because they all look the 
same as Figure 4. 
DISCUSSION 
The goal of this project was to further understanding of PAl -1 and vitronectin 
interactions using site-directed mutagenesis. Previous bacterial expression of the 
Somatomedin B domain of vitronectin revealed a number of essential amino acids 
required for binding including, Tyr-27, and Tyr-28 (13). Dr. Cynthia Peterson's lab has 
developed a way to express the full-length recombinant protein using a baculovirus 
expression system, as opposed to bacterially expressed fragments. Alanine mutants of 
Tyr-27, and Tyr-28, are the two mutants manipulated during this study. Unfortunately, 
large-scale expression of the two mutants was never achieved. Therefore, the Elisa 
competitive analysis of PAI-1 binding to vitronectin cannot be discussed in this paper. 
There are a number of hypotheses as to why the mutant vitronectin expressed well 
on a 3mL scale, but would not express on a larger scale, 20mL or 1L. One reason why the 
mutant vitronectin would not express on a large scale is the failure of the protease 
inhibitors to protect the protein. After the 1 L infected Hi5 cells were infected with the 
mutant bacmid DNA, the cells were spun down and the supernatant was stored in the 
refrigerator. A number of protease inhibitors was added to this supernatant including, 
PMSF, pepstatin, leupeptin, aprotinin, TPCK, and EDT A, in order to preserve the mutant 
vitronectin protein. One of these protease inhibitors may have been defective. In other 
words, one of the protease inhibitors may not have inhibited its target protease, resulting 
in the degradation of the mutant vitronectin protein. In addition, the concentration of 
protease inhibitors may not have been large enough to prevent all the proteases from 
degrading the mutant protein. Another possibility is that there was a protease degrading 
the mutant vitronectin that is unknown. Therefore, no protease inhibitor was added to 
prevent the unknown protease from denaturing the mutant vitronectin. 
In addition to the hypothesis that the protease inhibitors were defective in some 
way, other reasons could result in the lack of expression of the protein. The 
concentration of virus stock needed to express the protein on a 3mL scale, may not have 
been a large enough concentration of virus stock to express the protein on alL scale. A 
simple ratio was performed indicating 8.33mL of virus stock needed to express the 
protein on a lL scale. In addition, this same ratio was used to determine that 166.67/-lL 
of virus stock was needed to infect 20mL of cells. These calculations could have been 
made in error, or the volume of virus stock was not large enough in order to infect the 
volume of HiS cells. 
One other hypothesis as to why the mutant vitronectin would not express on a 
large scale is contamination. There is a possibility that each time a large-scale infection 
was performed the HiS cells were contaminated somehow. This contamination may have 
resulted in the lack of protein. 
In conclusion, there are a number of reasons that could result in the lack of large-
scale expression of the mutant vitronectin protein. The protease inhibitors may have been 
defective. The HiS cells could have been contaminated each time. The volume of virus 
stock may not have been large enough to infect a large quantity ofRi5 cells. All of these 
factors may have inhibited the project, and prevented the expression of protein. As a 
result of the lack of expression of mutant vitronectin on a large scale, ELISA assays were 
not performed. Although the project did not progress as far as desired, a great deal of 
knowledge was gained regarding restriction digest procedures, Western Blot procedures, 
manipulating bacteria as well as insect cells, and protein expression. Great thanks goes to 
the Peterson lab for harboring me for a year and their patience in teaching me is greatly 
appreciated. I also want to thank the Threshold program for providing me with such a 
wonderfulleaming opportunity. 
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